Table 3.
Yttrium-90 Selective Internal Radiation Therapy for Treatment of Unresectable CRLM
| Study | Design | Treatment | N | Prior treatments | Median OS, months (95% CI) | Median PFS, months | Adverse events |
|---|---|---|---|---|---|---|---|
| Saxena et al (2014)49 | Systematic review | Y90 | 979 (20 studies) | Chemo ± hepatic intervention | 12 (range, 8.3–36.0) | 9 (range, 6–16) | Not reported |
| Saxena et al (2015)45 | Retrospective, single-center cohort | Y90 | 302 | Chemo ± hepatic intervention | 10.5* | NR | None ≥ grade 3 |
| Hickey et al (2015)46 | Retrospective, multicenter cohort | Y90 | 531 | Any | 10.6 (8.8–12.4) | NR | 13% ≥ grade 3 |
| Abbott et al (2015)47 | Retrospective, single-center cohort | Y90 | 68 | Chemo ± hepatic intervention | 11.6* | NR | 7.3% ≥ grade 3 |
| Golfieri et al (2015)48 | Prospective, single-center case series | Y90 | 52 | Chemo ± hepatic intervention | 11.0 (8.0–14.0) | NR | 6% ≥ grade 3 |
| Van Hazel et al (2016)43 | Prospective, multicenter RCT | Chemo vs chemo + Y90 | 530 | None | NR | 10.2 (chemo) vs 10.7 (chemo + Y90); P=0.4 | 74.4% (chemo) vs 85.4% (chemo + Y90) grade ≥ 3; P=0.5 |
| Wasan et al (2017)42 | 3 multicenter RCTs (combined analysis) | Chemo vs chemo + Y90 | 1103 | None | 23.3 (chemo) vs 22.6 (chemo + Y90); P=0.6 | 10.3 (chemo) vs 11.0 (chemo + Y90); P=0.1 | Y90 group greater odds of grade ≥ 3 |
| Gibbs et al (2018)44 | 2 multicenter RCTs (combined analysis) | Chemo vs chemo + Y90, stratified by primary tumor side | 739 | None | RSP: 22.0 (chemo + Y90) vs 17.1 (chemo); P=0.01 LSP: 24.6 (chemo + Y90) vs 26.6 (chemo); P=0.3 |
RSP: 10.8 (chemo + Y90) vs 8.7 (chemo); P=0.06 LSP: 11.4 (chemo + Y90) vs 10.8 (chemo); P=0.4 |
RSP: No difference in grade ≥ 3 LSP: Y90 group greater odds of grade ≥ 3 |
| White et al (2019)2 | Prospective, multicenter cohort | None | 399 | Chemo ± hepatic intervention | 7.6 (6.9–8.3) | 3.0 (2.8–3.1) | 143 (36%) experienced an AE; 8% were ≥ grade 3 |
CRLM, colorectal liver-only or liver-dominant metastases; RCT, randomized controlled trial; Y90, yttrium-90 selective internal radiation therapy; chemo, chemotherapy; OS, overall survival; PFS, progression-free survival; RSP, right-sided primary tumor; LSP, left-sided primary tumor; NR, not reported; AE, adverse event.
*
95% CI and/or P value not reported.